Showing 5941-5950 of 9451 results for "".
DWTV Extra: GPP Awareness Day
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-gpp-awareness-day/36704/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, discusses the importance of educating more clinicians about generalized pustular psoriasis (GPP) and observing GPP Awareness Day on August 13.All Things Psoriasis With Dr. April Armstrong
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.Analyzing Safety Data From Level Up
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeAnalysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/videos/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discussesFDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/videos/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.Science of Skincare Summit 2024: On the FDA Approval of Emrosi for Rosacea
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-on-the-fda-approval-of-emrosi-for-rosacea/29276/At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts oFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/videos/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.DermWire TV: Maui Derm Highlights, Plus New and Emerging Treatments for HS and Acne
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-maui-derm-highlights-plus-new-and-emerging-treatments-for-hs-and-acne/20258/In this episode of DermWire TV, we recap the biggest news from Maui Derm 2024, including safety and efficacy studies on bimekizumab, deucravacitinib, and upadacitinib. Also from Maui Derm, Raj Chovatiya, MD, PhD, highlights new therapies to treat hidradenitis suppurativa and Julie Harper, MD, highliAdvances in Topicals for Skin Conditions
https://practicaldermatology.com/topics/psoriasis/advances-in-topicals-for-skin-conditions/20197/There are more topicals available today than ever before for acne, rosacea, and psoriasis, and even more are coming down the pike. Larry Green, MD, reviews the current topical landscape in dermatology and previews what’s in the pipeline.